Return on Equity (ROE)
Updated 104h ago
Sector Performance
47th percentileMET
13.0%
Sector Median
13.8%
Sector Avg
31.4%
Deep Analysis
Return on Equity (ROE) measures how much profit a company generates for each dollar of shareholders' equity — at 13.0%, MET earns $0.13 for every $1 of equity.
That figure sits just below the sector median of 13.8%, placing MET in the 47th percentile among its peers, meaning roughly half the sector has higher ROE and half lower. Year-over-year and quarter-over-quarter changes are not available (N/A), and there is no trend data for the last eight quarters, leaving only the single current value of 13.0%. Without any direction of change, the combination of an ROE slightly below the median and no trend information suggests a neutral risk profile — neither a clear competitive advantage nor an emerging weakness. This metric supports the overall NEUTRAL verdict on MET, as the ROE is near the sector middle with no historical movement to tilt the outlook toward opportunity or concern.
Frequently Asked Questions
What does the Return on Equity (ROE) tell investors about MET?
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
How is the Return on Equity (ROE) calculated?
Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.
Who are MET's closest peers by Return on Equity (ROE)?
The closest peers by Return on Equity (ROE) include: MRNA (-36.6%), FICO (-37.3%), XRAY (-37.7%), VRSN (-38.3%), MSCI (-45.3%).
The Formula
Net Income / Shareholders' Equity
Why It Matters
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Master MET's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full MET research report →MET
13.0%
Sector Median
13.8%
Sector Avg
31.4%
How MET's Return on Equity (ROE) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.